SAN DIEGO, May  16, 2025  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the following companies: Super Micro Computer, Inc. (NASDAQ: SMCI), Methode Electronics, Inc. (NYSE: MEI), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), New Fortress Energy Inc. (NASDAQ: NFE).

Super Micro Computer, Inc. (NASDAQ: SMCI)

Johnson Fistel, PLLP is investigating claims on behalf of Super Micro Computer, Inc. against certain officers and directors.

If you are a long-term shareholder of Super Micro, continuously holding your shares, you may have standing to hold the Company harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action: https://www.johnsonfistel.com/investigations/super-micro-computer-inc-nasdaq-smci

Previously a class action complaint was filed against the Company alleging the Company made false and misleading statements to the market. Super Micro consistently overreported sales and underreported expenses. The Company had re-hired multiple executives who had left after its previous accounting scandal. The Company had a much closer relationship with related parties than it portrayed to the market. The Company failed to cease exporting products to areas under restriction by the U.S. government due to the Russia-Ukraine war. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Super Micro, investors suffered damages.

Methode Electronics, Inc. (NYSE: MEI)

Johnson Fistel, PLLP is investigating claims on behalf of Methode Electronics, Inc. against certain of its officers and directors.

If you are a current, long-term shareholder of the Company, continuously holding your shares since June 23, 2022, you may have standing to hold the Company harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action: https://www.johnsonfistel.com/investigations/methode-electronics-inc

Previously a class action complaint was filed against the Company. The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Methode had lost highly skilled and experienced employees during the COVID-19 pandemic necessary to successfully complete Methode's transition from its historic low mix, high volume production model to a high mix, low production model at its Monterrey facility; (2) Methode's attempts to replace its General Motors center console production with more diversified, specialized products for a wider array of vehicle manufacturers and OEMs, in particular in the electric vehicle ("EV") space, had been plagued by production planning deficiencies, inventory shortages, vendor and supplier problems, and, ultimately, botched execution of Methode's strategic plans; (3) Methode's manufacturing systems at its critical Monterrey facility suffered from a variety of logistical defects, such as improper system coding, shipping errors, erroneous delivery times, deficient quality control systems, and failures to timely and efficiently procure necessary raw materials; (4) Methode had fallen substantially behind on the launch of new EV programs out of its Monterrey facility, preventing Methode from timely receiving revenue from new EV program awards; and (5) as a result, Methode was not on track to achieve the 2023 diluted earnings-per-share guidance or the 3-year 6% organic sales compound annual growth rate represented to investors and such estimates lacked a reasonable factual basis.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

Johnson Fistel, PLLP is investigating claims on behalf of Regeneron Pharmaceuticals, Inc. against certain of its officers and directors.

If you are a current, long-term shareholder of Regeneron, continuously holding shares since November 2, 2023, you may have standing to hold the Company harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. You can click or copy and paste the link below in a browser to join this action: https://www.johnsonfistel.com/investigations/regeneron-pharmaceuticals-inc

Previously, a class action complaint was filed against the Company. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that Regeneron paid credit card fees to distributors on the condition that distributors did not charge Eylea customers more to use a credit card; (2) that these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) that, as a result, Regeneron offered a price concession that lowered Eylea’s selling price; (4) that, because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron’s price concessions provided a competitive advantage; (5) that, as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; (6) that, by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

New Fortress Energy Inc. (NASDAQ: NFE)

Johnson Fistel PLLP is investigating potential claims on behalf of the Company against certain of its officers and directors.

If you have continuously owned New Fortress Energy Inc. shares since before September 20, 2022, submit your information below:

https://www.johnsonfistel.com/investigations/new-fortress-energy-inc

Previously a class action lawsuit was filed against the Company. According to the lawsuit, during the Class Period, defendants created the false impression that they possessed reliable information pertaining to New Fortress’ projected revenue outlook and anticipated growth while simultaneously minimizing the risk involved in New Fortress’ plan to have its Fast Liquefied Natural Gas (“LNG”) projects fully operational and to increase business growth globally. In reality, New Fortress’ Fast LNG projects failed to fulfill New Fortress’ public statements that its FLNG 1 project would be in service by March 2024. Even following the announcement that these delays were costing New Fortress upwards of $150 million per quarter, defendants continued to tout the speed at which New Fortress was building facilities. Defendants misled investors by providing the public with materially flawed statements of confidence and growth projections that did not account for these variables.

About Johnson Fistel, PLLP: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Colorado, and Idaho. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.

Achievements: In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs’ securities law firm in the United States, as determined by the total dollar value of final recoveries.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact: 
Johnson Fistel, PLLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
[email protected] or [email protected]